Remix Therapeutics’ REM-422, a First-in-Class mRNA Degrader of the MYB Oncogene, Demonstrates Anti-tumor Activity in Xenograft Models of Adenoid Cystic Carcinoma and Acute Myeloid Leukemia Portfolio News / By Libby Nunan Remix Therapeutics’ REM-422, a First-in-Class mRNA Degrader of the MYB Oncogene, Demonstrates Anti-tumor Activity in Xenograft Models of Adenoid Cystic Carcinoma and Acute Myeloid Leukemia Read More »
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models Portfolio News / By Libby Nunan Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models Read More »
Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session Portfolio News / By Libby Nunan Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session Read More »
Kimia Therapeutics Appoints Imran S. Haque, Ph.D. as Chief Technology Officer Portfolio News / By Libby Nunan Kimia Therapeutics Appoints Imran S. Haque, Ph.D. as Chief Technology Officer Read More »
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Portfolio News / By Karina Tin Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Read More »
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results Portfolio News / By Karina Tin RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results Read More »
Tenaya Therapeutics Announces Pricing of Public Offering Portfolio News / By Karina Tin Tenaya Therapeutics Announces Pricing of Public Offering Read More »
Eikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipeline Portfolio News / By Karina Tin Eikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipeline Read More »
ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones Portfolio News / By Karina Tin ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones Read More »
NGM Bio Announces First Participant Dosed in EMERALD Phase 2 Clinical Study of NGM120 for the Treatment of Hyperemesis Gravidarum (HG) in Pregnant Patients Portfolio News / By Karina Tin NGM Bio Announces First Participant Dosed in EMERALD Phase 2 Clinical Study of NGM120 for the Treatment of Hyperemesis Gravidarum (HG) in Pregnant Patients Read More »
